D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.0, a high estimate of $46.00 ...
BofA lowered the firm’s price target on 4D Molecular (FDMT) to $42 from $46 on Friday and kept a Buy rating on the shares. The firm notes 4D ...
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on ...
D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...
4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...
5 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below ...
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the ...
The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular edema (DME) candidate 4D-150. The company will only have to conduct a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback